Carcinogenic mechanisms related to immunosuppressive therapy

Cancer Treatment and Research

Volumn 146, Issue , 2009, Pages 123-132

  Perrett, Conal M ^a   Harwood, Catherine A ^b,c   McGregor, Jane M ^a   Karran, Peter ^d  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c BARTS HEALTH NHS TRUST   (United Kingdom)

^d IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN; GLUCOCORTICOID; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; TACROLIMUS; CARCINOGEN; IMMUNOSUPPRESSIVE AGENT;

ANTIINFLAMMATORY ACTIVITY; CANCER RISK; DOSE RESPONSE; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; KIDNEY ALLOGRAFT REJECTION; KIDNEY GRAFT REJECTION; LOW DRUG DOSE; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PSORIASIS; REVIEW; SKIN CANCER; SKIN CARCINOGENESIS; ULTRAVIOLET RADIATION; BIOLOGICAL MODEL; COMPLICATION; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

AZATHIOPRINE; CARCINOGENS; CYCLOSPORINE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; MODELS, BIOLOGICAL; ORGAN TRANSPLANTATION; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

EID: 77953678701     PISSN: 09273042     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-78574-5_11     Document Type: Review

References (52)

1. Pouteil-Noble C. Immunosuppressive treatments. In: Euvrard S, Kanitakis J, Claudy A (eds) Skin Diseases After Organ Transplantation. Paris: John Libbey Eurotext, 1998:17-28.
2. Berg D, Otley CC. Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management. J Am Acad Dermatol 2002; 47:1-17.
3. Kuypers DR. Benefit-risk assessment of sirolimus in renal transplantation. Drug Saf 2005; 28(2):153-81.
4. Morris JD, Eddleston AL, Crook T. Viral infection and cancer. Lancet 1995; 346(8977):754-8.
5. Glover MT, Deeks JJ, Raftery MJ et al. Immunosuppression and risk of non-melanoma skin cancer in renal transplant recipients. Lancet 1997; 349(9049):398
6. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370(9581):59-67.
7. Guba M, von Breitenbuch P, Steinbauer M et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8(2):128-35.
8. Luan FL, Hojo M, Maluccio M et al. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation 2002; 73(10):1565-72.
9. Mathew T, Kreis H, Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant 2004; 18(4):446-9.
10. Ducloux D, Carron PL, Rebibou JM et al. CD4 lymphocytopenia as a risk factor for skin cancers in renal transplant recipients. Transplantation 1998; 65(9):1270-2.
11. Gibson GE, O'Grady A, Kay EW et al. Langerhans cells in benign, premalignant and malignant skin lesions of renal transplant recipients and the effect of retinoid therapy. J Eur Acad Dermatol Venereol 1998; 10(2):130-1.
12. Bergfelt L. Langerhans cells, immunomodulation and skin lesions. A quantitative, morphological and clinical study. Acta Derm Venereol Suppl (Stockh) 1993; 180:1-37.
13. Otley CC, Coldiron BM, Stasko T, Goldman GD. Decreased skin cancer after cessation of therapy with transplant-associated immunosuppressants. Arch Dermatol 2001; 137(4):459-63.
14. Glover MT, Niranjan N, Kwan JT, Leigh IM. Non-melanoma skin cancer in renal transplant recipients: the extent of the problem and a strategy for management. Br J Plast Surg 1994; 42(2):86-9.
15. Jensen P, Hansen S, Moller B et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 1999; 40(2 pt 1):177-86.
16. Dantal J, HourmantM, Cantarovich D et al. Effect of long-term immunosuppression in kidneygraft recipients on cancer incidence: randomised comparison of two ciclosporin regimens. Lancet 1998; 351(9103):623-8.
17. Caforio AL, Fortina AB, Piaserico S et al. Skin cancer in heart transplant recipients: risk factor analysis and relevance of immunosuppressive therapy. Circulation 2000; 102(19 suppl 3):111222-7.
18. Chocair PR, Duley JA, Simmonds HA, Cameron JS. The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients. Transplantation 1992; 53(5):1051-6.
19. Ramsay HM, Harden PN, Reece S et al. Polymorphisms in glutathione S-transferases are associated with altered risk of nonmelanoma skin cancer in renal transplant recipients: a preliminary analysis. J Invest Dermatol 2001; 117(2):251-5.
20. Fryer AA, Ramsay HM, Lovatt TJ et al. Polymorphisms in glutathione S-transferases and non-melanoma skin cancer risk in Australian renal transplant recipients. Carcinogenesis (Oxf) 2005; 26(1):185-91.
21. Karagas MR, Cushing GL Jr, Greenberg ER et al. Non-melanoma skin cancers and glucocorticoid therapy. Br J Cancer 2001; 85(5):683-6.
22. IARC (International Agency for Research on Cancer). Monographs on the Evaluation of Carcinogenic Risk to Humans: Prednisone [446-86-6] 1987; 26(suppl 7):293
23. Kelly GE, Meikle W, Sheil AG. Effects of immunosuppressive therapy on the induction of skin tumors by ultraviolet irradiation in hairless mice. Transplantation 1987; 44(3):429-34.
24. Paul CF, Ho VC, McGeown C et al. Risk of malignancies in psoriasis patients treated with ciclosporin: a 5 y cohort study. J Invest Dermatol 2003; 120(2):211-6.
25. Bunney MH, Benton EC, Barr BB et al. The prevalence of skin disorders in renal allograft recipients receiving ciclosporin A compared with those receiving azathioprine. Nephrol Dial Transplant 1990; 5(5):379-82.
26. Shuttleworth D,Marks R, Griffin PJ, Salaman JR. Epidermal dysplasia and ciclosporin therapy in renal transplant patients: a comparison with azathioprine. Br J Dermatol 1989; 120(4):551-4.
27. Herman M, Weinstein T, Korzets A et al. Effect of ciclosporin A on DNA repair and cancer incidence in kidney transplant recipients. J Lab Clin Med 2001; 137(1):14-20.
28. Hiesse C, Larue JR, Kriaa F et al. Incidence and type of malignancies occurring after renal transplantation in conventionally and in ciclosporin-treated recipients: single-center analysis of a 20-year period in 1600 patients. Transplant Proc 1995; 27(4):2450-1.
29. IARC (International Agency for Research on Cancer). Monographs on the Evaluation of Carcinogenic Risk to Humans: Ciclosporin [79217-60-0] 1990; 50:77
30. Yarosh DB, Pena AV, Nay SL et al. Calcineurin inhibitors decrease DNA repair and apoptosis in human keratinocytes following ultraviolet B irradiation. J Invest Dermatol 2005; 125(5):1020-5.
31. Vamvakas S, Bahner U, Becker P et al. Impairment of DNA repair in the course of long-term hemodialysis and under ciclosporin immunosuppression after renal transplantation. Transplant Proc 1996; 28(6):3468-73.
32. Kelly GE, Meikle W, Sheil AG. Scheduled and unscheduled DNA synthesis in epidermal cells of hairless mice treated with immunosuppressive drugs and UVB-UVA irradiation. Br J Dermatol 1987; 117(4):429-40.
33. Sugie N, Fujii N, Danno K. Cyclosporin-A suppresses p53-dependent repair DNA synthesis and apoptosis following ultraviolet-B irradiation. Photodermatol Photoimmunol Photomed 2002; 18(4):163-8.
34. Canning MT, Nay SL, Pena AV, Yarosh DB. Calcineurin inhibitors reduce nuclear localization of transcription factor NFAT in UV-irradiated keratinocytes and reduce DNA repair. J Mol Histol 2006; 37(5-7.):285-91.
35. Queille S, Luron L, Spatz A et al. Analysis of skin cancer risk factors in immunosuppressed renal transplant patients shows high level of UV-specific tandem CC to TT mutations of the p53 gene. Carcinogenesis (Oxf) 2007; 28(3):724-31.
36. Hojo M, Morimoto T, Maluccio M et al. Ciclosporin induces cancer progression by a cellautonomous mechanism. Nature (Lond) 1999; 397(6719):530-4.
37. Koranda FC, Loeffler RT, Koranda DM, Penn I. Accelerated induction of skin cancers by ultraviolet radiation in hairless mice treated with immunosuppressive agents. Surg Forum 1975; 26:145-6.
38. IARC (International Agency for Research on Cancer). Monographs on the Evaluation of Carcinogenic Risk to Humans: Azathioprine [446-86-6] 1987; 26(suppl 7):47
39. Relling MV, Dervieux T. Pharmacogenetics and cancer therapy. Nat Rev Cancer 2001; 1: 99-108.
40. Tidd DM, Paterson AR. A biochemical mechanism for the delayed cytotoxic reaction of 6-mercaptopurine. Cancer Res 1974; 34(4):738-46.
41. Warren DJ, Andersen A, Slordal L. Quantitation of 6-thioguanine residues in peripheral blood leukocyte DNA obtained from patients receiving 6-mercaptopurine-based maintenance therapy. Cancer Res 1995; 55(8):1670-4.
42. Cuffari C, Seidman EG Latour S, Theoret Y. Quantitation of 6-thioguanine in peripheral blood leukocyte DNA in Crohn's disease patients on maintenance 6-mercaptopurine therapy. Can J Physiol Pharmacol 1996; 74(5):580-5.
43. Fairbanks LD, Bofill M, Ruckemann K, Simmonds HA. Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. Disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors. J Biol Chem 1995; 270(50):29682-9.
44. Tiede I, Fritz G, Strand S et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003; 111(8):1133-45.
45. Poppe D, Tiede I, Fritz G et al. Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins. J Immunol 2006; 176(1):640-51.
46. Hemmens VJ, Moore DE. Photochemical sensitization by azathioprine and its metabolites. II. Azathioprine and nitroimidazole metabolites. Photochem Photobiol 1986; 43(3):257-62.
47. O'Donovan P, Perrett CM, Zhang X et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 2005; 309(5742):1871-4.
48. Massey A, Xu YZ, Karran P. Photoactivation of DNA thiobases as a potential novel therapeutic option. Curr Biol 2001; 11(14);1142-6.
49. Al-Tassan N, Chmiel NH, Maynard J et al. Inherited variants of MYH associated with somatic G : CT : A mutations in colorectal tumors. Nat Genet 2002; 30(2):227-32.
50. Euvrard S, Ulrich C, Lefrancois N. Immunosuppressants and skin cancer in transplant patients: focus on rapamycin. Dermatol Surg 2004; 30:628-33.
51. de Fijter JW. Use of proliferation signal inhibitors in non melanoma skin cancer following renal transplantation. Nephrol Dial Transplant 2007; 22(suppl 1):123-6.
52. Sanchez-Fructuosu A, Conesa J, Perex Flores I, Ridao N et al. Conversion to sirolimus in renal transplant recipients with tumors. Transplant Proc 2006; 38(8):2451-2.